Shoichiro Sato¹, Epelbaum Stephane², Naohisa Hatakeyama¹, Shinji Fujikoshi¹, Hideaki Katagiri¹ (1.Eli Lilly Japan. K.K., Kobe, Japan, 2.Eli Lilly and Company. Indianapolis, USA)

Kazuya Igarashi^1,2, Kensaku Kasuga¹, Tamao Tsukie¹, Soichiro Shimizu³, Tetsunori Miyashita¹, Osamu Onodera², Takeshi Ikeuchi¹ (1.Department of Molecular Genetics, Brain Research Institute, Niigata University, Japan, 2.Department of Neurology, Brain Research Institute, Niigata University, Japan, 3.Center for Dementia-Related Diseases, Tokyo Medical University Hospital, Japan)

Sayuri Shima¹, Reiko Ohdake¹, Akihiko Takashima², Takahiko Tokuda³, Shinsuke Ishigaki⁴, Junichi Hata⁵, Epifanio Bagarinao⁶, Atsushi Kasai⁷, Yasuaki Mizutani¹, Akihiro Ueda⁸, Mizuki Ito⁹, Hirohisa Watanabe¹ (1.Department of Neurology, Fujita Health University School of Medicine, Japan, 2.Department of Life Science, Faculty of Science, Gakushuin University, Japan, 3.Department of Functional Brain Imaging, Institute for Quantum Medical Science, Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology (QST), Japan, 4.Molecular Neuroscience Research Center, Shiga University of Medical Science, Japan, 5.Graduate School of Human Health Sciences, Tokyo Metropolitan University, Japan, 6.Department of Integrated Health Sciences, Nagoya University Graduate School of Medicine, Japan, 7.MIG Co., Ltd, Japan, 8.Department of Neurology, Fujita Health University Okazaki Medical Center, Japan, 9.Department of Neurology, Fujita Health University Bantane Hospital, Japan)

Ryuta Morihara, Emi Nomura, Yumiko Nakano, Taijun Yunoki, Mami Takemoto, Toru Yamashita, Hiroyuki Ishiura (Departments of Neurology, Okayama University, Japan)